{"id":"W3169437264","doi":"10.1200/jco.2021.39.15_suppl.1001","title":"Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).","year":2021,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"ca_institutions":"BC Cancer Agency","funders":"Novartis Pharmaceuticals Corporation","keywords":"Medicine; Hazard ratio; Fulvestrant; Internal medicine; Breast cancer; Placebo; Oncology; Cancer; Nuclear medicine; Surgery; Confidence interval; Estrogen receptor; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001306756,0.0004348794,0.002757814,0.00008102599,0.00009727649,0.00001733836,0.0003581367,0.0003911288,0.0004184484],"category_scores_gemma":[0.0007700301,0.0002365539,0.0003846507,0.0004078696,0.0007029335,0.0003124929,0.00006944861,0.001438788,0.000003830509],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003538871,"about_ca_system_score_gemma":0.003705848,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004965048,"about_ca_topic_score_gemma":0.0008060203,"domain_scores_codex":[0.9934027,0.0009462906,0.003451266,0.0005744287,0.00112218,0.0005031691],"domain_scores_gemma":[0.9897849,0.002698668,0.004036696,0.0006030523,0.002356092,0.0005205969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8564014,0.008872553,0.01882021,0.00001409352,0.002844715,0.001186868,0.0002500478,0.0003275787,0.001628015,0.00002624797,0.0003858781,0.1092424],"study_design_scores_gemma":[0.669721,0.05202744,0.2562574,0.0005589139,0.001803226,0.0004673628,0.0003718619,0.00004575212,0.0009061275,0.0001200601,0.01739188,0.0003289278],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9874235,0.0004345973,0.0001080814,0.008824598,0.0009879627,0.0007275337,0.001029871,0.00002516658,0.0004386778],"genre_scores_gemma":[0.9933224,0.0006617847,0.002357641,0.001594392,0.001445713,0.00001930354,0.0002540138,0.00007002164,0.0002747312],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2374372,"threshold_uncertainty_score":0.9646387,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.05298804300520032,"score_gpt":0.4116209007185532,"score_spread":0.3586328577133529,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}